Gland Pharma Quarterly Results

Charts

YoY Net Sales (Quarterly)

Operating Margin

EPS Growth

POSITIVES

Revenue has shown consistent growth year-over-year, indicating strong demand for products.
Gross margins have improved, reflecting better operational efficiency and cost management.
The company has successfully expanded its product portfolio, enhancing its market competitiveness.

NEGATIVES

Net profit margins have experienced volatility, raising concerns about profitability sustainability.
R&D expenses have increased significantly, potentially impacting short-term profitability.
Sales growth has slowed in the latest quarter compared to previous quarters, indicating market saturation risks.

Field	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Jun 25
Revenue	1,208.69	1,373.42	1,545.15	1,537.45	1,401.71	1,405.83	1,384.05	1,505.62
Expenses	984.97	1,136.69	1,299.39	1,281.37	1,234.89	1,208.71	1,143.24	1,250.41
Operating Profit	223.72	236.73	245.76	256.08	166.82	197.12	240.81	255.21
Other Income	37.54	53.15	37.39	42.15	51.43	59.66	58.49	57.53
Interest	4.92	6.05	5.28	9.96	5.62	6.11	22.82	11.50
Depreciation	65.31	81.30	105.34	92.61	91.96	93.83	96.33	101.05
Profit Before Tax	261.27	289.89	283.16	298.23	218.24	256.78	299.30	312.74
Tax	67.16	95.81	91.30	105.81	74.48	93.25	94.61	97.26
Net Profit	194.10	194.08	191.86	192.42	143.76	163.53	204.69	215.48
Eps in Rs	11.79	11.78	11.65	11.68	8.73	9.93	12.42	13.08